Score Your Stock

US stock · figures in US dollars · scored on full-year results

Bio-Techne Bio-Techne Corp

TECH · Healthcare · Biotechnology
Top 47% of scored stocks
OkayTop 47% of scored stocks
Weak Spot

Bio-Techne scores 55/100 on fundamentals: in the top 47% of 503 scored S&P 500 stocks. Its strongest area is Financial Safety (100/100); its weakest is Price Fairness (0/100). It carries 1 warning flag: Weak Spot.

Best
Financial 100
Weakest
Price 0
  • Carries a Weak Spot flag

A financially strong, expensively priced stock, but price fairness needs attention.

What looks good
What to watch
Mkt capUS$ 11.4b#482 of 503 in the S&P 500EPSUS$ 1.16P/E62.4×✗ vs sector median 29.6×P/B5.4×✗ vs sector median 3.7×Div yield0%Bottom 26% in the S&P 50052w range · 100% of range43.2072.75
as of 31 Oct 2026

Nearby peers

Ranks #28 of 60 in Healthcare by score

#1Universal Health Services79#26Bristol Myers Squibb55#27Incyte55
#28Bio-Techne55
#29HCA Healthcare54#30Regeneron Pharmaceuticals54

One-Minute Summary

Why Bio-Techne scores 55

A financially strong, expensively priced stock, but price fairness needs attention.

What looks good
What to watch

Business Strength

40
Why 40?
Pillar score: (1 + 1 + 0 + 1 + 1) = 4 of 10 points → 40
Return on Equity (ROE)9%Okay4-Year Revenue Growth+2%/yrOkay4-Year Profit Growth-14%/yrWeakNet Profit Margin15%OkayQuarterly Momentum-0%Okay
Show 3 charts

Net Profit & Equity, with ROE

Net Profit ↓ -36.2%Equity ↑ +7.2%ROE % 8.6%
Net ProfitEquityROE %
285m168m73m182m2.0b2.1b1.9b2.1b202320242025202614.5%8.1%3.8%8.6%

Revenue & Net Profit, with Net Margin

Revenue ↑ +6.9%Net Profit ↓ -36.2%Net Margin % 15%
RevenueNet ProfitNet Margin %
1.1b1.2b1.2b1.2b285m168m73m182m202320242025202625.1%14.5%6%15%

Sales have been roughly flat for 4 years: the business isn't really growing, just maintaining.

Profit fell about 36.2% from where it was 4 years ago: the boom has cooled off.

Recent Quarters: Revenue & Net Profit (the last 8 quarters, scored)

Revenue ↑ +10.9%Net Profit ↑ +62.5%Net Margin % 17%
RevenueNet ProfitNet Margin %
290m297m316m317m287m296m311m321m34m35m23m-18m38m38m51m55mQ3'24Q4'24Q1'25Q2'25Q3'25Q4'25Q1'26Q2'2611.6%11.8%7.1%-5.6%13.3%12.8%16.4%17%
▼▲▼▼▲▲▲▲

Sales grew about 10.9% over the last 8 quarters: customers keep spending more with this company.

The company made a loss in at least one of the last 8 quarters: the bars below zero are losses, not profits.

Why 100?
Pillar score: (2 + 2 + 2) = 6 of 6 points → 100
Debt-to-Equity0.1×StrongCurrent Ratio4.6×StrongInterest Coverage26×Strong
Show 2 charts

Debt vs Equity, with D/E ratio

Total Debt ↓ -36.5%Equity ↑ +7.2%D/E 0.1×
Total DebtEquityD/E
455m420m444m289m2.0b2.1b1.9b2.1b20232024202520260.2×0.2×0.2×0.1×

Borrowings fell about 36.5% over 4 years: the company is steadily getting safer.

Short-term assets vs bills, with Current Ratio

Current Assets ↑ +19.8%Current Liabilities ↑ +27.4%Current Ratio 4.5×
Current AssetsCurrent LiabilitiesCurrent Ratio
622m617m608m744m129m159m176m164m20232024202520264.8×3.9×3.5×4.5×
Why 75?
Pillar score: (0 + 2 + 2 + 2) = 6 of 8 points → 75
Dividend Quality0%Weak
Payout ratio: 27%
Operating Cash FlowPositive & growingStrongFree Cash FlowPositive & growingStrongCash & Cash EquivalentsGrowing & covers near-term debtStrong
Show 3 charts

Operating vs Free Cash Flow

Operating CF ↑ +14.8%Free CF ↑ +21.8%
Operating CFFree CF
254m299m288m292m216m236m257m263m2023202420252026

The business generates real cash, and more of it each year: a very healthy sign.

Cash vs Total Debt

Cash ↑ +46.6%Total Debt ↓ -36.5%
CashTotal Debt
181m152m162m265m455m420m444m289m2023202420252026

Dividends per Share, with Yield

DPS (cents) → +0%Yield % 0.4%
DPS (cents)Yield %
88888888883232323220232024202520260.4%0.4%0.5%0.4%

Dividends per share have been maintained or raised: management shares the rewards with you.

Why 0?
Pillar score: (0 + 0 + 0) = 0 of 6 points → 0
P/E Ratio62.4×WeakP/B Ratio5.4×WeakPEG Ration/m (growth not measurable)Weak
Show chart

Share Price: Weekly Closes (not part of the score)

US$ 72.66US$ 57.92US$ 43.17Oct '25Feb '26Jun '26Oct '26

The share price is up about 16.8% over the past year.

Why 58?
Pillar score: (1 + 2 + 2 + 1 + 1 + 0) = 7 of 12 points → 58
Earnings ConsistencyUnevenOkayDebt Trend (4yr)FallingStrongShare Count Trend (4yr)-0%/yrStrongInventory vs Sales (4yr)+2.2 pp/yr vs salesOkayAsset Turnover Trend (4yr)+9%OkayQuarterly ConsistencyLoss in 1 of 8 quartersWeak
Show chart

Revenue vs Inventory, with Inventory % of Revenue

Revenue ↑ +6.9%Inventory ↑ +14%Inv. % of Rev. 16.1%
RevenueInventoryInv. % of Rev.
1.1b1.2b1.2b1.2b172m180m189m196m202320242025202615.1%15.5%15.5%16.1%
Ranks #28 of 60 in Healthcare by score

Sector peers

#1Universal Health Services79#26Bristol Myers Squibb55#27Incyte55
#28Bio-Techne (you)55
#29HCA Healthcare54#30Regeneron Pharmaceuticals54

Full Financial History

Every reported figure behind the score, year by year. Download it, or check it against the company's own annual report.

Financial YearRevenueNet ProfitOperating Cash FlowFree Cash FlowCapExCashTotal DebtEquityCurrent AssetsCurrent LiabilitiesTotal AssetsTotal LiabilitiesInventoryDividendsReturn on Equity (ROE)Net Profit MarginDebt-to-EquityCurrent RatioInterest CoverageDividend Payout RatioDiv yieldP/E RatioP/B RatioPEG Ratio
2026US$ 1.2bUS$ 181.9mUS$ 292.1mUS$ 263.2mUS$ -28.9mUS$ 264.7mUS$ 289.1mUS$ 2.1bUS$ 744.4mUS$ 163.7mUS$ 2.6bUS$ 478.5mUS$ 195.7mUS$ 32.0m9%15%0.1×4.6×26.0×27%0%62.4×5.4×-
2025US$ 1.2bUS$ 73.4mUS$ 287.6mUS$ 256.6mUS$ -31.0mUS$ 162.2mUS$ 444.1mUS$ 1.9bUS$ 608.3mUS$ 175.8mUS$ 2.6bUS$ 639.1mUS$ 189.4mUS$ 32.0m4%6%0.2×3.5×12.6×69%1%125.4×4.8×-
2024US$ 1.2bUS$ 168.1mUS$ 299.0mUS$ 236.1mUS$ -62.9mUS$ 151.8mUS$ 419.5mUS$ 2.1bUS$ 617.4mUS$ 159.4mUS$ 2.7bUS$ 635.0mUS$ 179.7mUS$ 32.0m8%15%0.2×3.9×12.8×30%0%68.8×5.6×-
2023US$ 1.1bUS$ 285.3mUS$ 254.4mUS$ 216.1mUS$ -38.2mUS$ 180.6mUS$ 455.0mUS$ 2.0bUS$ 621.5mUS$ 128.5mUS$ 2.6bUS$ 672.2mUS$ 171.6mUS$ 32.0m15%25%0.2×4.8×31.2×18%0%42.0×6.1×8.7